---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-015683"
form_type: "8-K/A"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T08:36:31.444583+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeuroOne stockholders approve 2025 Equity Incentive Plan and reverse stock split

## Summary
- Approved 2025 Equity Incentive Plan authorizing up to 3M new shares plus returning shares from prior plan.
- Approved reverse stock split at ratio of 1:2 to 1:15, with exact ratio to be set by the Board.
- David Rosa re-elected as Class II director with 11.7M votes for, 381.7K withheld, 6.0M broker non-votes.
- Ratified Baker Tilly U.S., LLP as independent auditor for FY2025 with 18.1M votes for, 7.4K against.
- Adjournment proposal also approved, with 16.8M votes for.

## SEC filing metadata
- accession: 0001213900-25-015683
- form_type: 8-K/A
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390025015683/0001213900-25-015683-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390025015683/ea0231612-8ka1_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-015683
- JSON: https://secwatch.observer/filing/0001213900-25-015683.json
- Plain text: https://secwatch.observer/filing/0001213900-25-015683.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.